The vitamin C trials that failed in the 1980s and the intravenous ascorbate research being conducted today are not testing the same thing, and the reason comes down to a ceiling the human body imposes on how much vitamin C can enter the blood by mouth.
That ceiling is well characterized in the federal nutrition literature. Eating five to nine servings of fruits and vegetables daily produces steady-state plasma vitamin C concentrations of 80 micromoles per liter or less. Pharmacokinetic modeling published in Annals of Internal Medicine predicted that even the maximum tolerated oral regimen, 3 grams every four hours, would push peak plasma concentrations only to about 220 micromoles per liter. The same modeling predicted 13,400 micromoles per liter for a single 50-gram intravenous dose.
Before going further, the essential caveat: intravenous vitamin C is not an approved cancer treatment. It remains investigational; no regulator has cleared it for treating any cancer, and nothing in this pharmacology justifies substituting it for standard therapy.
The Body's Limits on Oral Absorption
Three mechanisms working together keep oral vitamin C in a narrow range regardless of how much someone swallows.
Intestinal absorption is saturable. The transporters that move vitamin C across the gut wall have finite capacity, and once occupied, additional vitamin C passes through unabsorbed. The National Institutes of Health notes that above 1 gram per day, absorption falls below 50% and the unmetabolized remainder is excreted in urine. This is also why very large oral doses commonly cause diarrhea.
Tissue accumulation removes a portion from circulation. Renal handling removes more: the kidney reabsorbs vitamin C at low plasma concentrations but excretes the excess once concentrations rise, which is the origin of the observation that high-dose supplements produce expensive urine.
Intravenous administration bypasses the absorption limit entirely. Ascorbate enters the bloodstream directly, and while the kidney still clears it, concentrations reach levels oral dosing cannot approach. Peak concentrations as high as 15,000 micromoles per liter have been described for 100-gram infusions, in the millimolar range rather than the micromolar range.
That is a difference of roughly two orders of magnitude, which in pharmacological terms means a different exposure entirely.
The Trials That Produced the Contradiction
In the 1970s, Ewan Cameron and Linus Pauling reported that high-dose vitamin C improved quality of life and survival time in patients with terminal cancer. Mayo Clinic researchers led by Charles Moertel subsequently ran randomized, double-blind, placebo-controlled trials in which patients with advanced colorectal cancer received 10 grams of vitamin C daily by mouth and fared no better than those given a placebo. The treatment was judged ineffective.
The discrepancy sat largely unexplained for decades, and vitamin C acquired a reputation as a disproven cancer therapy.
The route explains much of it. The Mayo Clinic trials administered vitamin C orally. Cameron and Pauling administered it both orally and intravenously. Pharmacokinetic work led by Mark Levine's group at the National Institutes of Health established that the oral doses used at Mayo could not produce the plasma concentrations achievable intravenously, and that the same dose given by vein, as in the Pauling studies, would reach concentrations more than 25 times higher.
That study measured concentrations in 17 healthy volunteers across doses from 0.015 to 1.25 grams and modeled the range from 1 to 100 grams. Its authors concluded that the Mayo Clinic studies neither support nor refute possible effects of intravenously administered vitamin C on cancer. The study did not test cancer outcomes. It established that route determines exposure.
The Proposed Mechanism at Pharmacologic Concentrations
At extracellular concentrations above roughly 1,000 micromoles per liter, ascorbate has been observed in laboratory work to be toxic to cancer cells.
The proposed explanation inverts vitamin C's familiar role. At dietary concentrations, it acts as an antioxidant. At millimolar concentrations in extracellular fluid, it behaves as a pro-drug, generating hydrogen peroxide outside cells. Normal cells clear hydrogen peroxide efficiently using catalase and related enzymes. Many cancer cell lines have impaired antioxidant defenses and clear it less well, which is the proposed basis for selective toxicity.
This mechanism has been demonstrated in cell culture and animal models. It has not been established as the operative mechanism in patients, and laboratory selectivity does not reliably predict clinical benefit.
Clinical research is ongoing at academic centers, typically testing high-dose ascorbate as an addition to standard chemotherapy rather than as a replacement. A randomized phase 2 trial in pancreatic cancer reported improved survival when high-dose intravenous ascorbate was added to chemotherapy. A phase 2 result is a signal that justifies larger trials, not evidence sufficient to change practice.
The Distance Between Research and the Clinic Selling Infusions
The gap that matters most for readers is between this research and the commercial infusion market.
Intravenous vitamin C is widely sold at wellness and integrative clinics, often at doses far below those used in oncology research and without the monitoring those protocols require. A clinic offering an infusion is not conducting the research described here, and the existence of active trials does not validate what is being sold.
Real risks accompany high-dose infusion. People with glucose-6-phosphate dehydrogenase deficiency can experience severe hemolysis, which is why oncology protocols screen for it beforehand. High-dose ascorbate is metabolized partly to oxalate and can cause kidney stones or oxalate nephropathy, particularly in people with impaired kidney function. The infusion volume itself can be a problem for patients with heart or kidney disease. Ascorbate also interferes with some glucometers, producing falsely elevated readings that can lead to dangerous insulin dosing in people with diabetes.
Anyone with cancer considering this should raise it with their oncologist rather than pursuing it separately, both because of interaction concerns with active treatment and because clinical trial participation is the setting where it is studied with monitoring. Patients can search ClinicalTrials.gov or ask their cancer center about open ascorbate trials. MedicalDaily has covered how rigorous laboratory findings translate slowly into approved therapy in other fields, and what a completed approval pathway looks like. Cost pressures shape access to approved cancer drugs as well, a subject MedicalDaily has followed through federal price negotiation.
Key Questions Answered
Why did the early vitamin C cancer trials fail? The Mayo Clinic trials used oral dosing, which cannot raise blood concentrations high enough to produce a pharmacologic effect. The earlier Cameron and Pauling work used both oral and intravenous administration.
How different are the blood levels? Eating five to nine servings of produce daily yields 80 micromoles per liter or less. The maximum tolerated oral regimen peaks around 220. Modeling predicted 13,400 micromoles per liter for a 50-gram intravenous dose, and concentrations as high as 15,000 have been described for 100-gram infusions.
Why can't oral dosing reach those levels? Intestinal absorption is saturable, tissue uptake removes some, and the kidney excretes the excess once plasma concentrations rise. Intravenous administration bypasses the absorption limit.
What is the proposed mechanism? At millimolar concentrations, ascorbate acts as a pro-drug generating hydrogen peroxide outside cells. Normal cells clear it efficiently; many cancer cell lines clear it less well. This has been shown in cells and animals, not established in patients.
Is intravenous vitamin C an approved cancer treatment? No. It is investigational. No regulator has cleared it for treating any cancer, and it should not replace standard therapy.
What are the risks? Severe hemolysis in people with G6PD deficiency, kidney stones and oxalate nephropathy particularly with impaired kidney function, fluid volume problems in heart or kidney disease, and false glucometer readings that can lead to dangerous insulin dosing.
What should a patient with cancer do? Raise it with their oncologist rather than pursuing it independently, because of interaction concerns and because clinical trials provide the monitoring these protocols require.
